适形放疗治疗腹膜后淋巴结转移的疗效分析  

Efficiency of stereotactic radiotherapy in the treatment of retroperitoneal lymph node metastasis

作　　者：单娟[1] 袁翎[1] 刘新菊[1] 

机构地区：[1]河南省肿瘤医院放疗科,河南郑州450003

出　　处：《中国现代医学杂志》2010年第11期1688-1689,1692,共3页China Journal of Modern Medicine

摘　　要：目的探讨分析适形放疗腹膜后淋巴结转移的疗效。方法 71例腹膜后淋巴结转移患者,给予适行放疗,180～200cGy/f,80%～90%以上的等剂量线包括靶区,腹膜后总剂量40～60Gy。结果 CR29.58%(21/71),PR47.89%(34/71),其他(NC+PD)22.54%(16/71),总有效率(CR+PR)77.46%。1、2和3年生存率分别为59.15%(42/71)、22.54%(16/71)和9.86%(7/71)。中位生存期15.3个月。多因素分析显示原发病、放疗剂量、症状缓解影响预后,而淋巴结转移大小、是否有癌栓、放疗体积与预后无关。结论三维适形放疗治疗腹膜后淋巴结转移安全有效;放疗剂量及疗效影响预后。[Objective]To analyze the clinical effects of stereotactic radiotherapy in the treatment of retroperitoneal lymph node metastasis. [Methods]71 patients with retroperitoneal lymph node metastasis were treated with stereotactic radiotherapy in our department. The dose was 1.8～2.0 cGy per fraction, the total dose of retroperitoneal were ranged from 40 Gy to 60 Gy, five times a week. The planned target volume was encompassed by more than 80% to 90% isodose line.[Results]The overall response rate（CR＋PR） was 77.46%, the 1, 2, 3-years survival rates were 59.15%（42/71）, 22.54%（16/71）, 9.86%（7/71）. The median survival time was 15.3 months. Multivariate analysis showed that original illness, radiotherapy dose, partial and complete response were related to identify predictors of outcome, and the volume of radiotherapy, the size of metastatic-lymph node, tumor thrombi were not related to the outcome. [Conclusion]Stereotactic radiotherapy is an safe and effective treatment for retroperitoneal lymph node metastasis. The radiotherapy dose, partial and complete response are related to the outcome.

关 键 词：腹膜后淋巴结转移 三维适形放疗 多因素分析 

分 类 号：R816.5[医药卫生—放射医学]